Created

SECTION 2: Hazards identification

OSHA Emergency Overview: As a result of the physical presentation of the product, the risk to health and the environment in the normal handling of the product is expected to be low.

Health hazards

(Acute & Chronic) Target Organs: Skin, eye, Central Nervous System (CNS) and cardiovascular system. As a result of the physical presentation of the product, the risk to health in the normal handling of the product is expected to be low. Acute Effects: Systemic absorption of this product may result in toxic effects on the CNS and the cardiovascular system. Allergic reactions may also occur in sensitive individuals. Significant adverse effects on intact skin are unlikely. Contact with mucous membranes may cause irritation and/or numbness (loss of sensation).

Potential chronic health

Chronic effects are unlikely to occur. Repeated exposure to high levels of an amide anesthetic in animals produced adverse effects on the liver and CNS. Signs & Symptoms of Overexposure Inhalation (unlikely route of exposure) and Ingestion: Systemic effects may include nervousness, confusion, drowsiness, blurred vision, vomiting, tremors, convulsions, respiratory depression, slowing of the heart rate, blood pressure drop and unconsciousness. Local effects may include allergic reaction, irritation and numbness (loss of sensation). Created on: 11.16.04 Replaces version dated: 09.29.04 Product name: Oraqix® Section 2 continued Skin / mucous membranes: May cause mild irritation. Repeated or prolonged contact may cause sensitization in a small proportion of the population. May cause numbness. Eyes: May cause irritation, excessive watering (lacrimation) and eye damage, blurred vision and numbness.

Medical Conditions Generally Aggravated by Exposure

Prilocaine may cause methemoglobinemia in high doses and so may aggravate congenital or idiopathic methemoglobinemia. Adverse effects could be more pronounced in those individuals with pre-existing diseases of central nervous system or cardiovascular system or those receiving medications that affect these systems (such as antihypertensive agents, antiarrhythmic agents or CNS depressant medications). Effects could also be more pronounced in individuals with a compromised ability to metabolize and clear active ingredients from the blood and body tissues (such as severe liver or kidney disease). LD50 / LC50 Mixture: Unknown

Principle Routes of Exposure

Indicators Carcinogenicity Indicators Inhalation Yes NTP No Skin Yes IARC No Ingestion Yes